Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2020 Earnings Conference Call - Final Transcript

Nov 23, 2020 • 04:30 pm ET


Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal Fourth Quarter and Year-End 2020 Financial Results Call. [Operator Instructions] There will be a question-and-answer session at the end of the prepared remarks. [Operator Instructions] I would now like to turn the call over to Jennifer Viera, Senior Director, Investor Relations. Please go ahead.

Jennifer Viera

Thank you, operator and thanks to everyone for joining us this afternoon. The news release with our fiscal fourth quarter and 2020 year-end financial results was issued this afternoon and is available on our website. On the call today is Dr. Jay Luly President and Chief Executive Officer; Paul Mellett, our Chief Financial Officer; and other members of Enanta's senior management team.

Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our research and development pipeline and financial projections, all of which involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from those statements. A description of these risks is in our most recent Form 10-Q and other periodic reports filed with the SEC. Enanta does not undertake any obligation to update any forward-looking statements made during this call.

I'd now like to turn the call over to Dr. Jay Luly, President and CEO. Jay?

Jay R. Luly

Thank you, Jennifer, and good afternoon everyone. Throughout 2020, we made meaningful advances across our pipeline. Today, I'm excited to review this progress and to share our plans for multiple catalysts in 2021. Looking ahead, we believe that we are in a unique position to leverage our years of drug discovery experience to deliver new medicines to patients. Not only do we have a robust and growing internal portfolio which I'll review momentarily, but our efforts are informed by our previous successes, including the discovery of two products, which are currently marketed by AbbVie as part of its leading treatment for chronic HCV infection.

In the beginning of the year, we announced our program for human metapneumovirus or hMPV, and in March, we began working to find the treatment for COVID-19. I'm proud and appreciative of my colleagues for their efforts and rapidly responding to the pandemic and for the nimble and creative thinking they applied to translate our extensive experience in virology, notably respiratory virology to fight this global challenge. Taking a step back by focusing on these two respiratory viruses, combined with our work in respiratory syncytial virus, we are establishing our position as one of only a few biotechnology companies explicitly developing a broad portfolio in the respiratory virus treatments.

We also advanced our hepatitis B compound EDP-514, a novel core inhibitor that displays potent anti-HBV activity in vitro at multiple steps on the HBV in life cycle. In February, we announced positive results from Part 1 of our Phase 1a/1b clinical study of EDP-514 in healthy subjects, which supported further evaluation of once daily dosing and Part 2 of the